Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. It is recognized as a high-efficacy drug that likely results in a significant reduction of individuals with relapses at 24 months.
• Four systematic reviews/meta-analyses were analyzed to collate information on Ponvory's efficacy and safety profile in comparison to other Disease Modifying Therapies (DMTs).
• Compared to Natalizumab, Cladribine, Alemtuzumab, and Ublituximab, which are regarded as top-tier DMTs due to their higher effectiveness over two years against placebo, Ponesimod does not rank among these but still maintains a favorable position within the treatment landscape.
• In terms of safety profiles among high-efficacy DMTs: Alemtuzumab shows higher rates of adverse events, while Ponesimod exhibits no significant differences in terms of serious adverse events, suggesting it has a comparatively balanced risk-benefit ratio.
• The studies did not provide detailed insights into population types or subgroup specifics beyond mentioning broad adult populations with Relapsing Remitting Multiple Sclerosis (RRMS). Thus, specific considerations such as age or gender-related performance were not extensively covered for Ponesimod in comparison to other DMTs.
• Although its efficacy may be lower than some monoclonal antibodies like Natalizumab, based on the studies reviewed, its competitive safety profile along with similar general adverse event rates across high-efficacy DMTs makes it an important consideration in the management of RRMS.